63 related articles for article (PubMed ID: 9667950)
1. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
3. Immunocytokines: amplification of anti-cancer immunity.
Davis CB; Gillies SD
Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
[TBL] [Abstract][Full Text] [Related]
4. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
Pancook JD; Becker JC; Gillies SD; Reisfeld RA
Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
[TBL] [Abstract][Full Text] [Related]
5. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
6. Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost JD; Rakhmilevich A; Hank JA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 1999 Aug; 48(5):219-29. PubMed ID: 10478638
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin sensitivity of Chinese hamster ovary cells expressing human transferrin receptors with differing internalization rates.
Recht LD; Raso V; Davis R; Salmonsen R
Cancer Immunol Immunother; 1996 Jul; 42(6):357-61. PubMed ID: 8830739
[TBL] [Abstract][Full Text] [Related]
9. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
Ren Z; Zhang X; Fu YX
Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
[TBL] [Abstract][Full Text] [Related]
10. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs.
Wang Z; Ramakrishna R; Wang Y; Qiu Y; Ma J; Mintzlaff D; Zhang H; Li B; Hammell B; Lucia MS; Pomfret E; Su AA; Washington KM; Mathes DW; Wang Z
Eur J Pharmacol; 2024 Apr; 968():176408. PubMed ID: 38367684
[TBL] [Abstract][Full Text] [Related]
11. Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate.
Yamaguchi T; Tsurumi H; Kitamura K; Otsuji E; Miyagaki T; Kotani T; Takahashi T
Jpn J Cancer Res; 1993 Nov; 84(11):1190-4. PubMed ID: 8276723
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice.
Lutz EA; Jailkhani N; Momin N; Huang Y; Sheen A; Kang BH; Wittrup KD; Hynes RO
PNAS Nexus; 2022 Nov; 1(5):pgac244. PubMed ID: 36712341
[TBL] [Abstract][Full Text] [Related]
13. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.
Bootz F; Neri D
Drug Discov Today; 2016 Jan; 21(1):180-189. PubMed ID: 26526566
[TBL] [Abstract][Full Text] [Related]
14. Armed antibodies for cancer treatment: a promising tool in a changing era.
Danielli R; Patuzzo R; Ruffini PA; Maurichi A; Giovannoni L; Elia G; Neri D; Santinami M
Cancer Immunol Immunother; 2015 Jan; 64(1):113-21. PubMed ID: 25314912
[TBL] [Abstract][Full Text] [Related]
15. Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
Pabani A; Gainor JF
Clin Cancer Res; 2023 Oct; 29(19):3841-3849. PubMed ID: 37227449
[TBL] [Abstract][Full Text] [Related]
16. Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity.
Santollani L; Zhang YJ; Maiorino L; Palmeri JR; Stinson JA; Duhamel LR; Qureshi K; Suggs JR; Porth OT; Pinney W; Msari RA; Wittrup KD; Irvine DJ
bioRxiv; 2024 Jan; ():. PubMed ID: 38260254
[TBL] [Abstract][Full Text] [Related]
17. Correlation of In Vitro Kinetic Stability to Preclinical In Vivo Pharmacokinetics for a Panel of Anti-PD-1 Monoclonal Antibody Interleukin 21 Mutein Immunocytokines.
Cook KD; Tran T; Thomas VA; Devanaboyina SC; Rock DA; Pearson JT
Drug Metab Dispos; 2024 Feb; 52(3):228-235. PubMed ID: 38135505
[TBL] [Abstract][Full Text] [Related]
18. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.
Rotta G; Gilardoni E; Ravazza D; Mock J; Seehusen F; Elsayed A; Puca E; De Luca R; Pellegrino C; Look T; Weiss T; Manz MG; Halin C; Neri D; Dakhel Plaza S
EMBO Mol Med; 2024 Apr; 16(4):904-926. PubMed ID: 38448543
[TBL] [Abstract][Full Text] [Related]
19. Immunocytokines with activity-on-demand by combination with small molecule inhibitors.
Müller D
EMBO Mol Med; 2024 Apr; 16(4):670-671. PubMed ID: 38448542
[TBL] [Abstract][Full Text] [Related]
20. Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
